📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
ICRA Assigns [ICRA]AA (Stable) and [ICRA]A1+ Ratings to Sai Life Sciences' Rs 768.60 Cr Debt
ICRA Limited has assigned high-grade credit ratings to Sai Life Sciences Limited for its total debt facilities of Rs 768.60 crore. The long-term fund-based facilities of Rs 550 crore received an [ICRA]AA (Stable) rating, while short-term non-fund-based facilities of Rs 218.60 crore were assigned [ICRA]A1+. These ratings reflect a strong credit profile and a high degree of safety regarding the timely servicing of financial obligations. The facilities are spread across major lenders including State Bank of India, IndusInd Bank, and Bank of Baroda.
Key Highlights
Assigned [ICRA]AA (Stable) rating for Rs 550.00 crore long-term fund-based facilities
Assigned [ICRA]A1+ rating for Rs 218.60 crore short-term non-fund-based facilities
Total rated debt instruments amount to Rs 768.60 crore across multiple banking partners
State Bank of India holds the largest share of rated limits at Rs 230.60 crore
The 'Stable' outlook indicates ICRA's expectation of maintained credit quality in the medium term
💼 Action for Investors
Investors should view these high investment-grade ratings as a sign of financial robustness and low credit risk. No immediate action is required, but the ratings support a positive long-term outlook for the company's capital structure.
Sai Life Sciences Q3 FY26 PAT Surges 86% to ₹100 Cr; EBITDA Margins Expand to 34.4%
Sai Life Sciences reported a strong performance for Q3 FY26, with consolidated revenue growing 27% YoY to ₹556 crore. The company's profitability saw a significant boost as EBITDA rose 54% to ₹191 crore, driven by a 605 bps margin expansion to 34.4%. For the nine-month period, PAT grew by a massive 199% to ₹245 crore, reflecting robust operational leverage and healthy demand in the CDMO segment. The company is aggressively investing in capacity, with ₹405 crore of the planned ₹700 crore FY26 capex already deployed.
Key Highlights
Q3 FY26 Revenue increased 27% YoY to ₹556 crore, with CDMO services contributing 65% of total revenue.
EBITDA margins expanded significantly by 605 bps to 34.4%, outperforming the company's long-term guidance of 28-30%.
Net Profit (PAT) for the quarter jumped 86% YoY to ₹100 crore, while 9M FY26 PAT grew 199% to ₹245 crore.
Added 7 molecules to the late-phase and commercial pipeline during the year, taking the total to 43 molecules.
Invested ₹405 crore in capital expenditure out of a ₹700 crore plan for FY26 to expand manufacturing capacity by ~450KL.
💼 Action for Investors
Investors should monitor the company's execution of its ₹700 crore capex plan and its ability to maintain margins above 30% as new capacities come online. The strong pipeline growth in late-phase molecules provides good revenue visibility for the coming years.
Sai Life Sciences Q3 FY26 PAT Jumps 86% to ₹100 Cr; 9M PAT Surges 199%
Sai Life Sciences reported a robust Q3 FY26 with revenue growing 27% YoY to ₹556 crore and PAT increasing 86% to ₹100 crore. The nine-month performance was even stronger, with PAT surging 199% to ₹245 crore on the back of 43% revenue growth. EBITDA margins expanded significantly by 605 bps to 34% in Q3, driven by improved capacity utilization and operational efficiencies. The company is on track with its ₹700 crore FY26 capex plan, having already invested ₹405 crore to enhance its CRDMO capabilities.
Key Highlights
9M FY26 Net Profit (PAT) skyrocketed by 199% YoY to ₹245 Cr from ₹82 Cr in the previous year.
Q3 FY26 Revenue grew 27% YoY to ₹556 Cr, while EBITDA rose 54% to ₹191 Cr.
EBITDA margins expanded to 34% in Q3 FY26 compared to 28% in Q3 FY25.
Invested ₹405 Cr in capital expenditure as of date against a total FY26 plan of ₹700 Cr.
Successfully completed 8 customer audits during the quarter with zero critical observations.
💼 Action for Investors
The company is demonstrating exceptional growth and margin expansion that outperforms broader industry trends. Investors should maintain a positive outlook while monitoring the execution of the remaining ₹300 Cr capex and the sustainability of the 30%+ EBITDA margins.
Sai Life Sciences Q3 FY26 PAT Jumps 91% YoY to ₹976.3 Million; Revenue Up 28%
Sai Life Sciences reported a robust performance for the quarter ended December 31, 2025, with revenue from operations growing 28.1% YoY to ₹5,491.79 million. Net profit surged by 91.2% YoY to ₹976.30 million, even after accounting for a one-time exceptional loss of ₹82.93 million due to new labor code liabilities. The company has successfully utilized its entire IPO proceeds of ₹9,098.84 million, primarily for debt repayment, which has significantly reduced finance costs from ₹216.59 million to ₹80.61 million YoY. Operational efficiency is reflected in the Profit Before Tax, which grew 92.1% YoY to ₹1,304.69 million.
Key Highlights
Revenue from operations increased 28.1% YoY to ₹5,491.79 million from ₹4,286.02 million.
Net Profit (PAT) grew 91.2% YoY to ₹976.30 million compared to ₹510.57 million in the previous year.
Finance costs significantly decreased to ₹80.61 million from ₹216.59 million YoY following debt repayment.
Exceptional loss of ₹82.93 million recorded due to increased gratuity and leave liabilities under new Labour Codes.
Fully utilized IPO proceeds of ₹9,098.84 million, with ₹7,200 million used for debt repayment.
💼 Action for Investors
The strong top-line growth and significant reduction in interest costs post-IPO debt repayment make this a positive result. Investors should monitor if the company can maintain these improved margins as it scales operations.
Sai Life Sciences Partners with Mabtech to Launch Immunology Research Hub in Boston
Sai Life Sciences has announced a strategic collaboration with Swedish firm Mabtech to establish its Boston laboratory as a US execution and demonstration hub for the EYRA platform. This partnership enables Sai to offer advanced immunology assay services, including high-sensitivity multiplex cytokine and phenotyping workflows, to global biopharma clients. The EYRA platform allows for the simultaneous detection of dozens of analytes in a single run, significantly enhancing Sai's discovery and translational research capabilities. This move strengthens the company's competitive position in high-growth sectors like immuno-oncology, vaccines, and cellular therapy.
Key Highlights
Sai’s Boston site becomes a co-marketed US execution hub for the Mabtech EYRA platform
Joint delivery of advanced immunology services targeting immuno-oncology and cellular therapy
EYRA platform enables simultaneous detection of dozens of analytes with minimal hands-on time
Strategic expansion of US discovery operations to accelerate biopharma development timelines
💼 Action for Investors
Investors should monitor the impact of this high-tech service expansion on Sai's US revenue growth and client acquisition. This collaboration enhances the company's value proposition in the specialized CRDMO market.
Sai Life Sciences Receives GST Penalty Order of ₹4.93 Crore for FY 2018-22
Sai Life Sciences Limited has received a tax order from the Additional Commissioner, Ranga Reddy GST Commissionerate, imposing a penalty of ₹4.93 crore. The demand is based on alleged excess Input Tax Credit (ITC) availment and discrepancies between B2B supply records and government portal data for the period FY 2018-19 to FY 2021-22. The company has stated its intention to file an appeal against this order, expressing confidence in a favorable outcome. While the penalty is significant, the company does not currently expect a material financial impact on its operations.
Key Highlights
Penalty of INR 4,93,36,015 (₹4.93 crore) imposed under Section 74 of the CGST/TGST Act.
Order relates to alleged excess ITC availment and B2B supply record differences.
The investigation covers a four-year period from financial year 2018-19 to 2021-22.
Company plans to contest the order through the formal appellate process.
Management currently assesses no material financial impact pending the appeal outcome.
💼 Action for Investors
Investors should monitor the progress of the appeal as the penalty amount is noteworthy, though not immediately detrimental to the company's liquidity. No immediate action is required unless the appellate authority upholds the demand.
SAILIFE: Order passed u/s 73(9) of GST Act, demand of ₹32.86 Cr
Sai Life Sciences received an order from the Deputy Commissioner of Commercial Taxes (Audit), Bidar, DGSTO Kalaburagi under Section 73(9) of the Integrated Goods and Services Tax Act, 2017. The order demands ₹16,28,46,397 towards IGST, ₹13,31,50,353 as interest, and ₹3,25,69,279 as penalty, totaling ₹32.86 Cr. The demand relates to alleged excess availment of Input Tax Credit in GSTR-3B compared to GSTR-2A for FY 2021-22. The company plans to file an appeal and anticipates a favorable outcome, expecting no material financial impact.
Key Highlights
IGST demand of ₹16,28,46,397
Interest demand of ₹13,31,50,353
Penalty of ₹3,25,69,279
Order passed under Section 73(9) of the GST Act
Demand related to FY 2021-22
💼 Action for Investors
Investors should monitor the progress of the appeal filed by the company. While the company anticipates a favorable outcome, any adverse development could potentially impact its financials.
SAILIFE: Order passed under GST Act with demand of ₹8.8 Cr
Sai Life Sciences has received an order from the Joint Commissioner of Commercial Taxes (Appeals), Kalaburagi under the Karnataka Goods and Services Tax Act, 2017. The order demands IGST of ₹4,62,36,986, Cess of ₹291,659, Interest of ₹3,20,77,995, and a Penalty of ₹92,76,563, totaling approximately ₹8.8 crores. The demand relates to alleged excess availment of ITC and discrepancies in B2B supply records for FY 2020-21. The company plans to appeal the order and anticipates a favorable outcome, expecting no material financial impact.
Key Highlights
IGST demand of ₹4,62,36,986
Cess demand of ₹291,659
Interest demand of ₹3,20,77,995
Penalty of ₹92,76,563 imposed
Order passed under Section 107 (11) of the GST Act, 2017
💼 Action for Investors
Investors should monitor the progress of the appeal process. While the company expects a favorable outcome, any adverse ruling could potentially impact its financials.